Satellos Bioscience Inc (MSLE)

$11.25 -0.66 (-5.54%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 105,000
Avg Vol 15,576
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 39%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
PennyScam
PennyScam Apr. 18 at 8:06 PM
$MSLE Have you looked at the value of your wholly owned ICO subsidiary? Great value here. Crazy K
1 · Reply
Florestan
Florestan Apr. 17 at 2:16 AM
$MSLE ;)
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 16 at 7:16 PM
$MSLE So whether it’s updated TRAILHEAD data in a few months or top-line BASECAMP data before year-end, we feel investors will return to Satellos, and the stock will rebound.
1 · Reply
WBinthehouse
WBinthehouse Apr. 16 at 4:29 PM
$MSLE up 9% on 35k shares. lol
0 · Reply
WBinthehouse
WBinthehouse Apr. 13 at 5:16 PM
$MSLE up 10% on 76k shares. Anemic. Can’t even get out if need be lol.
1 · Reply
PennyScam
PennyScam Apr. 13 at 5:13 AM
$MSLE Neither am I. Ck
0 · Reply
WBinthehouse
WBinthehouse Apr. 11 at 5:44 AM
$MSLE got cut in half from high after RS. Not surprised.
0 · Reply
viber7
viber7 Apr. 10 at 3:39 PM
$MSLE risk analysis.
1 · Reply
focafoca99
focafoca99 Apr. 9 at 7:54 PM
$MSLE is previewing its appearance at the Bloom Burton healthcare conference.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 8 at 11:50 PM
$MSLE Leerink Partners $20 Buy 221% Upside Initiated 04/06/26 H.C. Wainwright $11 Buy 77% Upside Reiterated 03/30/26 Cantor Fitzgerald $52 NPV Buy 732% Upside Initiated 03/11/26 Leede Financial $16 Buy 157% Upside Reiterated 03/11/26 Oppenheimer $40 Buy 542% Upside Reiterated 02/25/26 Canaccord - outdated
0 · Reply
Latest News on MSLE
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Feb 6, 2026, 8:30 AM EST - 2 months ago

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience IPO Registration Document (F-10)

Feb 5, 2026, 4:09 PM EST - 2 months ago

Satellos Bioscience IPO Registration Document (F-10)

PennyScam
PennyScam Apr. 18 at 8:06 PM
$MSLE Have you looked at the value of your wholly owned ICO subsidiary? Great value here. Crazy K
1 · Reply
Florestan
Florestan Apr. 17 at 2:16 AM
$MSLE ;)
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 16 at 7:16 PM
$MSLE So whether it’s updated TRAILHEAD data in a few months or top-line BASECAMP data before year-end, we feel investors will return to Satellos, and the stock will rebound.
1 · Reply
WBinthehouse
WBinthehouse Apr. 16 at 4:29 PM
$MSLE up 9% on 35k shares. lol
0 · Reply
WBinthehouse
WBinthehouse Apr. 13 at 5:16 PM
$MSLE up 10% on 76k shares. Anemic. Can’t even get out if need be lol.
1 · Reply
PennyScam
PennyScam Apr. 13 at 5:13 AM
$MSLE Neither am I. Ck
0 · Reply
WBinthehouse
WBinthehouse Apr. 11 at 5:44 AM
$MSLE got cut in half from high after RS. Not surprised.
0 · Reply
viber7
viber7 Apr. 10 at 3:39 PM
$MSLE risk analysis.
1 · Reply
focafoca99
focafoca99 Apr. 9 at 7:54 PM
$MSLE is previewing its appearance at the Bloom Burton healthcare conference.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 8 at 11:50 PM
$MSLE Leerink Partners $20 Buy 221% Upside Initiated 04/06/26 H.C. Wainwright $11 Buy 77% Upside Reiterated 03/30/26 Cantor Fitzgerald $52 NPV Buy 732% Upside Initiated 03/11/26 Leede Financial $16 Buy 157% Upside Reiterated 03/11/26 Oppenheimer $40 Buy 542% Upside Reiterated 02/25/26 Canaccord - outdated
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 8 at 11:48 PM
$MSLE
0 · Reply
viber7
viber7 Apr. 8 at 11:44 PM
$MSLE @WBinthehouse This company and CAPR target markets are similar. Marketcap of CAPR is about 15X that of MSLE. Two obvious risks of MSLE. One, will trials be successful? 4 patients so far with double in muscle strength plus favorable proteomic biomarker data suggest good odds of success. Second, several years of trials with need to raise money and lots of dilutions ahead, as you have said. So perhaps MSLE is fairly valued vs CAPR considering the trial risk and dilution needed. Maybe successful trial odds are as high as 50%, and dilution factor of 2 makes MSLE undervalued. If you think success odds are 20% and dilution factor is 3, then MSLE is fairly valued vs CAPR. CAPR is unique in having cardiac benefits which would take many more years to prove for MSLE. Thoughts?
2 · Reply
steven5120
steven5120 Apr. 7 at 1:12 PM
$MSLE $MSCL Yesterday I published a follow up podcast interview with @Satellos Bioscience CEO Frank Gleeson found at https://youtu.be/CpLi7uAs_uM?si=QoqXUcwZf6L8QwKw
0 · Reply
WBinthehouse
WBinthehouse Apr. 7 at 12:41 AM
$MSLE i made a comment first time discovering this ticker that outstanding shares were high and RS was a possibility and I got a ton of flack from pumpers. After the RS I said it’s going back to pennies. More flack. Historical attrition in DMD clinical development is notably high, especially when moving from early to late phases. This is a well documented challenge in the space and one of the key reasons why positive signals don’t always translate to later success. DMD derisking really happens with robust, placebo controlled functional data in the target population. Positive results could drive major re rating. Bottom line still got a long ways to go and PPS will suffer with possibilities of more dilution and RS. There’s a better entry point in the Phase 2 pediatric readout in Q4 2026.
0 · Reply
WBinthehouse
WBinthehouse Mar. 31 at 11:44 PM
$MSLE What’s going on here? Where’s all the pumpers? Told you this is years away lol. All invested here will lose all their money from more RS and dilutions. Sorry not sorry.
2 · Reply
erevnon
erevnon Mar. 30 at 11:04 AM
HC Wainwright & Co. maintains Satellos Bioscience $MSLE at Buy and raises the price target from $1.2 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
topstockalerts
topstockalerts Mar. 30 at 11:01 AM
Pre Market Top Gainers PT2 $ASTC $ROMA $HOLO $MSLE $LTRN
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 8:22 PM
After Hours Top Gainers $ITOC $NXTT $BRZE $PAVS $MSLE
0 · Reply
Florestan
Florestan Mar. 22 at 10:21 AM
$MSLE we may be stuck and range bounded until Q4 readout of the pediatric cohort.
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 21 at 1:11 AM
$MSLE glad I sold half at 12, riding the free money. We aren't even at half time, keep selling I'll take your shares back.
0 · Reply
topstockalerts
topstockalerts Mar. 19 at 5:33 PM
$MSLE super low liquidity, moves can get exaggerated quickly. Needs careful risk management.
0 · Reply
WBinthehouse
WBinthehouse Mar. 18 at 3:51 PM
$MSLE lol. Where’s all the Bulls with their pump posters. What happened?
0 · Reply